"Conotoxin Polypeptide K-Cptx-Bt102, and Method for Preparation Threof and Application Thereof" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Lin, Zhilong; Wen, Bo; Tong, Ting; Liu, Jie; Du, Chaoqin; Mo, Fen; Peng, Chao; Shi, Qiong, filed on September 30, 2014, was
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventor Margolin, David H., filed on May 10, 2017, was made available online on November 2, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Genzyme Corporation. The following quote wa
"New Indication of Cardiovascular Drugs for Preparation of Cancer Inhibition Pharmaceutical Composition" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Chen, Chiu-Hung; Chuang, Show-Mei; Hsiao, Nai-Wan; Liang, Ruei-Yue; Tan, Xiao-Tong, filed on October 23, 2015, was
In the news release, Caligor Holdco, LLC, Leader in Strategic Clinical Trial Services, Acquires The Coghlan Group, issued 16- Nov-2017 by Caligor Holdco, LLC over PR Newswire, we are advised by the company that there have been multiple changes. Caligor Rx, Leader in Strategic Clinical Trial Services, Acquires The Coghlan Group. SECAUCUS, New Jersey
The Association of American Cancer Institutes issued the following news release:. The Association of American Cancer Institutes opposes the Centers for Medicare and Medicaid Services' Medicare Programs: Hospital Outpatient Prospective Payment Systems rule, released on November 1. The rule will cut hospital 340 B reimbursement from average sales pri
NEW HAVEN- Achillion Pharmaceuticals, Inc. today reported preliminary proof-of-concept results from group 1 of its ongoing Phase 2, open-label, 14- day study of ACH-4471 for patients with C3 glomerulopathy or immune complex-mediated membranoproliferative glomerulonephritis. Tom Barbour, Royal Melbourne Hospital, Melbourne, Australia, Department of.
Under the Paperwork Reduction Act of 1995, Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the Gen
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today presented updated data from the dose expansion cohort of the Phase 1 study evaluating single agent ivosidenib in patients with progressive low grade isocitrate dehydrogenase-1 mutant glioma. The data were presented today in a
By a News Reporter-Staff News Editor at Health& Medicine Week Allergan plc announced that it has received an Imported Drugs License from the Chinese Food and Drug Administration to market Ozurdex for the treatment of adult patients with macular edema following either Branch Retinal Vein Occlusion or Central Retinal Vein Occlusion.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced the company has initiated submission of a rolling New Drug Application to the U.S. Food and Drug Administration for patisiran, an investigational RNAi therapeutic targeting transthyretin, for the treatment of hereditary ATTR amyloidosis. The rolling submission all
New report of Ambulatory Surgery Center Market Report communicates about the manufacturing process. The process is analysed thoroughly with respect three points, viz. raw material and equipment suppliers, various manufacturing associated costs (mater...
-Arcturus Therapeutics Ltd., a leading RNA medicines company, announced today the completion of its previously announced merger with Alcobra Ltd., effective as of November 15, 2017. Pursuant to the merger, the holders of shares of Arcturus Therapeutics common stock outstanding immediately prior to the merger received 0.293 shares of Alcobra ordinar
AstraZeneca today announced that the US Food and Drug Administration has approved a new indication for FASLODEX, expanding the indication to include use with abemaciclib, a CDK4/6 inhibitor, for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 negative advanced or metastatic breast cancer in women with disease...
AstraZeneca has announced that the US Food and Drug Administration has approved a new indication for Faslodex, expanding the indication to include use with abemaciclib, a CDK4/6 inhibitor, for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 negative advanced or metastatic breast cancer in women with disease...
Nov. 16 Philadelphia has ended negotiations with NHS Human Services on a contract under which NHS would have run drug-treatment and behavioral-health operations at Girard Medical Center and the associated Goldman Clinic, a methadone center. Both are part of the bankrupt North Philadelphia Health System. Gladstein said the city still intends to si
According to a report by Grand View Research, the global biotechnology market is expected to reach USD 727.1 billion by 2025. Regen Biopharma, Inc., Idera Pharmaceuticals, Inc., Inovio Pharmaceuticals Inc., OncoMed Pharmaceuticals Inc., ImmunoGen, Inc.. Development and introduction of product offerings by a number of large entities is a significant
PETACH TIKVA, Israel Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that its previously majority owned subsidiary OphthaliX, Inc. has successfully completed a merger with Wize Pharma Ltd.. As a result of the merger, C
Dina Titus, D- Nev., issued the following news release:. Dina Titus of Nevada's First Congressional District released the following statement after the Congressional Budget Office estimated that the GOP's tax scheme will slash $136 billion from Medicare, the Affordable Care Act, and other direct-spending programs if the disastrous proposal becomes
Cerecor Inc. and TRx Pharmaceuticals, LLC today announced that the companies have entered into a purchase agreement in which Cerecor will acquire TRx, including subsidiary Zylera Pharmaceuticals, LLC and its franchise of commercial medications led by Poly-Vi-Flor and Tri-Vi-Flor and a merger agreement in which Cerecor will acquire Zylera Phar
The Patient Access Network Foundation issued the following news release:. And the Nov. 11 Economy& Business article "Pricey specialty drugs force seniors to make hard choices" accurately highlighted the incredible dilemma faced by seniors on Medicare who need expensive specialty medications to treat their illnesses. This document was posted showing
Thanks in part to nearly two decades of research at Cincinnati Children's Hospital Medical Center, the FDA has approved benralizumab, the first drug designed to specifically deplete eosinophils as a treatment for asthma. The FDA approved benralizumab as an add-on maintenance treatment for severe asthma with eosinophil involvement.
By a News Reporter-Staff News Editor at Drug Week CMP Pharma announced that CaroSpir , the first and only FDA- approved oral liquid dosage form of the potassium-sparing diuretic spironolactone, is now available. CaroSpir was approved by the FDA on August 4, 2017 and is now available through normal retail distribution. CaroSpir is available in 1
President of Epilepsy Foundation of Pakistan and noted neurophysician of the country, Dr Fowzia Siddiqui has expressed serious concerns on ongoing black marketing of epilepsy medicines and urged the government to take a strong notice of this human issue on urgent basis. She said hundreds of thousands of epilepsy patients have been suffering a lot d
SUMMARY: The Food and Drug Administration is correcting a notice entitled "Controlled Correspondence Related to Generic Drug Development; Draft Guidance for Industry; Availability" that appeared in the Federal Register of November 3, 2017. FOR FURTHER INFORMATION CONTACT: Lisa Granger, Office of Policy, Food and Drug Administration, 10903 New Hamps
Amir Kalali, will be interviewing Dr. William Carson, CEO of Otsuka Pharmaceutical Co., Ltd., and Andrew Thompson, president and CEO of Proteus Digital Health Eddie Martucci, CEO, and Adam Gazzaley, Chief Scientific Advisor, Akili Interactive Labs, and Bakul Patel, Center Director for Digital Health, FDA at CNS Summit 2017.. Otsuka and Proteus Digi